Entropy Technologies LP Has $724,000 Stake in Exelixis, Inc. (NASDAQ:EXEL)

Entropy Technologies LP lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 18.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,731 shares of the biotechnology company’s stock after acquiring an additional 3,431 shares during the quarter. Entropy Technologies LP’s holdings in Exelixis were worth $724,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Empowered Funds LLC bought a new stake in Exelixis during the 4th quarter worth about $7,455,000. Paragon Capital Management Inc. bought a new stake in shares of Exelixis during the fourth quarter valued at approximately $1,642,000. Longboard Asset Management LP bought a new stake in shares of Exelixis during the fourth quarter valued at approximately $245,000. Spire Wealth Management increased its holdings in shares of Exelixis by 49.9% in the fourth quarter. Spire Wealth Management now owns 9,010 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 3,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Exelixis by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 60,553 shares of the biotechnology company’s stock worth $2,016,000 after purchasing an additional 5,690 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Insider Activity at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 41,588 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $34.36, for a total value of $1,428,963.68. Following the sale, the executive vice president now owns 288,665 shares in the company, valued at approximately $9,918,529.40. The trade was a 12.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the transaction, the executive vice president now directly owns 486,059 shares of the company’s stock, valued at $17,823,783.53. This represents a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 111,588 shares of company stock valued at $3,981,864. 2.85% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. UBS Group increased their price objective on Exelixis from $30.00 to $34.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. Piper Sandler lifted their price objective on Exelixis from $36.00 to $37.00 and gave the stock an “overweight” rating in a research report on Monday, January 13th. Oppenheimer cut Exelixis from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $41.00 to $33.00 in a report on Friday, January 24th. Guggenheim reaffirmed a “buy” rating on shares of Exelixis in a research note on Wednesday, January 22nd. Finally, Truist Financial boosted their price target on shares of Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $36.06.

Exelixis Price Performance

Shares of Exelixis stock opened at $32.81 on Wednesday. The company has a market capitalization of $9.37 billion, a P/E ratio of 21.03, a price-to-earnings-growth ratio of 0.63 and a beta of 0.53. The business has a 50-day moving average of $34.30 and a two-hundred day moving average of $30.71. Exelixis, Inc. has a 1 year low of $20.01 and a 1 year high of $37.59.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 22.43% and a return on equity of 20.99%. On average, equities analysts anticipate that Exelixis, Inc. will post 1.74 EPS for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.